- Home
- QGEN vs HALO Comparison
QGEN vs HALO Comparison
Compare QGEN & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QGEN
- HALO
- Stock Information
- Founded
- QGEN 1986
- HALO 1998
- Country
- QGEN Netherlands
- HALO United States
- Employees
- QGEN N/A
- HALO N/A
- Industry
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QGEN Health Care
- HALO Health Care
- Exchange
- QGEN Nasdaq
- HALO Nasdaq
- Market Cap
- QGEN 9.1B
- HALO 7.4B
- IPO Year
- QGEN 1996
- HALO N/A
- Fundamental
- Price
- QGEN $45.14
- HALO $56.07
- Analyst Decision
- QGEN Buy
- HALO Buy
- Analyst Count
- QGEN 8
- HALO 9
- Target Price
- QGEN $50.53
- HALO $63.56
- AVG Volume (30 Days)
- QGEN 1.5M
- HALO 3.5M
- Earning Date
- QGEN 05-07-2025
- HALO 05-06-2025
- Dividend Yield
- QGEN 2.92%
- HALO N/A
- EPS Growth
- QGEN N/A
- HALO 55.40
- EPS
- QGEN 0.42
- HALO 3.76
- Revenue
- QGEN $2,002,874,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- QGEN $6.11
- HALO $25.77
- Revenue Next Year
- QGEN $6.10
- HALO $18.01
- P/E Ratio
- QGEN $107.32
- HALO $14.92
- Revenue Growth
- QGEN 3.31
- HALO 25.64
- 52 Week Low
- QGEN $37.63
- HALO $42.01
- 52 Week High
- QGEN $47.93
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- QGEN 66.03
- HALO 48.34
- Support Level
- QGEN $41.77
- HALO $54.00
- Resistance Level
- QGEN $43.01
- HALO $55.25
- Average True Range (ATR)
- QGEN 0.70
- HALO 2.53
- MACD
- QGEN 0.24
- HALO 0.14
- Stochastic Oscillator
- QGEN 93.82
- HALO 42.01
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.